Amotiv Limited (AOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amotiv Limited (AOV) has a cash flow conversion efficiency ratio of 0.090x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$68.96 Million ≈ $49.88 Million USD) by net assets (CA$767.27 Million ≈ $555.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Amotiv Limited market cap and net worth for the company's overall valuation and market capitalisation.
Amotiv Limited - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Amotiv Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amotiv Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amotiv Limited ranked by their cash flow conversion efficiency. Explore Amotiv Limited (AOV) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
-0.205x |
|
AECI Ltd
JSE:AFE
|
0.035x |
|
Hamaton Automotive Technology Co Ltd
SHE:300643
|
0.035x |
|
Brightspire Capital Inc
NYSE:BRSP
|
0.012x |
|
Guizhou Taiyong Changzheng Technology Co Ltd Class A
SHE:002927
|
-0.004x |
|
Steel Strips Wheels Limited
NSE:SSWL
|
0.055x |
|
Universal Cement Corp
TW:1104
|
0.030x |
|
Sinotherapeutics Inc. A
SHG:688247
|
N/A |
Annual Cash Flow Conversion Efficiency for Amotiv Limited (2014–2025)
The table below shows the annual cash flow conversion efficiency of Amotiv Limited from 2014 to 2025. View latest Amotiv Limited stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$767.27 Million ≈ $555.03 Million |
CA$68.96 Million ≈ $49.88 Million |
0.090x | +96.96% |
| 2024-12-31 | CA$795.11 Million ≈ $575.17 Million |
CA$36.28 Million ≈ $26.24 Million |
0.046x | -5.18% |
| 2023-12-31 | CA$746.87 Million ≈ $540.28 Million |
CA$35.94 Million ≈ $26.00 Million |
0.048x | -1.83% |
| 2022-12-31 | CA$825.86 Million ≈ $597.41 Million |
CA$40.48 Million ≈ $29.28 Million |
0.049x | -7.50% |
| 2021-12-31 | CA$842.02 Million ≈ $609.10 Million |
CA$44.62 Million ≈ $32.28 Million |
0.053x | +484.77% |
| 2020-12-31 | CA$886.24 Million ≈ $641.09 Million |
CA$-12.21 Million ≈ $-8.83 Million |
-0.014x | -374.21% |
| 2019-12-31 | CA$915.11 Million ≈ $661.97 Million |
CA$4.60 Million ≈ $3.32 Million |
0.005x | +190.14% |
| 2018-12-31 | CA$1.03 Billion ≈ $745.11 Million |
CA$-5.74 Million ≈ $-4.15 Million |
-0.006x | -123.54% |
| 2017-12-31 | CA$991.21 Million ≈ $717.02 Million |
CA$23.46 Million ≈ $16.97 Million |
0.024x | +57.32% |
| 2016-12-31 | CA$979.72 Million ≈ $708.71 Million |
CA$14.74 Million ≈ $10.66 Million |
0.015x | +26.49% |
| 2015-12-31 | CA$642.06 Million ≈ $464.46 Million |
CA$7.64 Million ≈ $5.52 Million |
0.012x | +609.11% |
| 2014-12-31 | CA$478.99 Million ≈ $346.49 Million |
CA$803.34K ≈ $581.13K |
0.002x | -- |
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more